Pfizer launches new website for Dupuytren’s disease
pharmafile | June 12, 2012 | News story | Medical Communications, Sales and Marketing | Dupuytren's disease, Pfizer, Xiapex, it is in your hands
Pfizer has released a new interactive video and website aimed at helping people with Dupuytren’s disease, a debilitating hand condition.
The video marks the launch of ‘Dupuytren’s disease – It is in your hands’, a European campaign funded by Pfizer in partnership with the European Men’s Health Forum.
The campaign aims to educate those who are living with Dupuytren’s disease and highlight the importance of seeking medical advice from their healthcare professional.
The disease is a medical condition of the hand and fingers and affects up to 13% of the European population.
It can gradually advance into Dupuytren’s contracture, where the affected finger or fingers permanently bend inwards into the palm of the hand. Although not life-threatening, the condition can limit patients’ lives.
Pfizer currently markets Xiapex (collagenase clostridium histolyticum), a non-surgical treatment option for Dupuytren’s contracture in adult patients with a palpable cord.
A central part of the ‘Dupuytren’s disease – It is in your hands’ campaign is an interactive video, which is available to view on YouTube.
The video illustrates the personal impact of Dupuytren’s contracture, by allowing the viewer to choose to undertake everyday actions as experienced by a person with the condition.
A website has also been created at www.itisinyourhands.eu to provide further information about the condition and tools such as a Dupuytren’s disease symptoms checker.
Dr Ian Banks, president of the European Men’s Health Forum, said: “It may seem obvious, but we are so reliant upon having good use of our fingers and hands for everyday tasks that we take them for granted.
“The new video helps to educate us all on how Dupuytren’s contracture can limit the home, social and working life of anyone affected, causing distress, frustration and embarrassment.”
Low awareness
Despite the potential impact of the condition, Pfizer says that there is low public awareness of Dupuytren’s disease across Europe.
In research commissioned by Pfizer amongst the general public in 12 European countries, eight out of ten (86%) people across Europe have never heard of it.
Pfizer hopes that its new programme will increase awareness about the disease, and potentially increase the uptake of treatments – such as its own – for the condition.
Ben Adams is the reporter for Pharmafocus and InPharm.com and DigiBlog site author. He can be contacted via: email or Twitter.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
